It's not been the easiest year to raise funding, but Houston startup founders managed to secure over $160 million in VC or grant funding last quarter. Photo via Getty Images

The second quarter of 2023 looked a lot like the first when it came to venture capital funding for Houston companies. The whole country — affected by inflation, geopolitical instability, and other factors — has seen a trying time for investment opportunities.

Houston's performance is far from unique. Globally, VC funding is down — a reported 18 percent from Q1 to Q2, per Crunchbase. Year over year, that's a 49 percent decrease from 2022's Q2.

According to InnovationMap reporting, 10 Houston-based, Houston-founded, or soon-to-be Houston-headquartered companies announced VC or grant funding between April and June. Here's a roundup of these second quarter deals — click on each story to read more.


Houston-founded e-commerce unicorn Cart.com raises $60M series C 

Cart.com has secured its unicorn status at a $1.2B valuation with latest round of venture capital funding. Image via Cart.com

A Houston-founded software company — officially a unicorn company, valued at $1 billion or more — has announced the details of its latest fundraise.

Cart.com, which provides a suite of software solutions for commerce and logistics enablement, closed its $60 million series C equity funding round with a $1.2 billion valuation. Investors in the round included B. Riley Venture Capital, Kingfisher Investment Advisors, Snowflake Ventures, Prosperity7 Ventures, Legacy Knight, and more.

According to a news announcement from the company, Cart.com will use the funding for international expansion, continued product development, and to meet increased client demand. Continue reading.

Houston e-commerce company P97 Networks  raises another $40M round to support growth

P97 Networks has again raised $40 million to support its growth. Photo via Getty Images

For the second time in just over a year, a Houston business that provides mobile commerce and digital marketing to the mobility and fuel industries has raised $40 million.

P97 Networks, which has developed a cloud-based mobile commerce platform that helps brands securely do business with customers, announced that it has closed its series C round at $40 million. The equity financing round was led by Portage and included participation from existing investors. The fresh funding will go to support growth strategy.

"In this highly connected world, retail brands are looking for new ways to increase consumer engagement — the power of network effects in the digital world will be a key contributor to revenue growth and margins," says Donald Frieden, CEO of P97 Networks, in a news release. "With consumers of all ages further adopting mobile payment solutions, we are proud to have built the leading connected commerce and digital marketing platform for the convenience retail, energy marketing, and transportation industry." Continue reading.

Podcast: Houston home tech startup SmartAC.com raises $22M to grow sales

Josh Teekell, founder and CEO of SmartAC.com, joins the Houston Innovators Podcast to discuss the latest from his company, which just closed its series B. Photo courtesy

A Houston startup that combines unique sensor technology with software analysis has raised its next round of funding to — according to Founder and CEO Josh Teekell — turbocharge its sales.

SmartAC.com launched in 2020, emerging from stealth with $10 million raised in a series A. Over the past almost three years, the company has firmed up its hardware, developed its software, and pivoted slightly from selling directly to consumers to adopting a B2B approach.

Now, Teekell says he's focused on turbocharging sales to these contractors, and he's going to do that with the funding raised in the series B round that closed this month. He says the company will also grow its team that goes out to deploy the technology and train the contractors on the platform.

"This funding really buys us a couple years of runway through the end of next year and allows us to focus on getting to cash flow breakeven, which is right around our wheelhouse of our abilities here in the next 12 months," Teekell says. "In general, we've accomplished everything we'd be able to accomplish on the hardware side, and now it's just about deployment."

The $22 million SmartAC.com has raised came from local investors. Teekell, who hasn't announced the full list of the round's investors, explains that while traditionally startups might have more opportunity on the coasts for raising money, it's not hard to sell Houstonians on the benefits of SmartAC.com's optimized air conditioning. Continue reading.

Houston fintech startup Brassica raises $8M seed round led by Mercury

A Houston fintech startup is aiming to modernize banking and investing — and has received fresh funding to do it. Photo via Getty Images

A Houston startup has raised millions for its fintech platform — and the company didn't have to go very far to find its lead investor.

Brassica Technologies Inc. closed its seed round at $8 million with Houston-based Mercury Fund leading the round. Valor Equity Partners, Long Journey Ventures, NGC Fund, Neowiz, Broadhaven Ventures, Armyn Capital, VC3DAO, Alpha Asset Management (Korea), and other global FinTech investors participated in the round as well.

The startup's platform has "institutional-grade solutions for the new era of private investing and alternative assets," per the release. Serving the alternative assets industry, Brassica's tools can easily integrate with any operating system to provide proprietary technology and unique regulatory licenses. The technology aims to modernize key banking and investing infrastructure to help enterprises safely grow their business and protect their customer assets. Continue reading.

Houston immunotherapy company 7 Hills Pharma to use $13.5M CPRIT grant to further develop cancer treatments

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas. Continue reading.

Seattle biotech co. OncoResponse to move to Houston thanks to $13.3M grant from CPRIT

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release. Continue reading.

Houston biotech startup CellChorus secures $2.3M SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences. Continue reading.

Health tech startup Rosarium Health raises $1.7M, plans Houston HQ

Rosarium Health, a member of the Texas Medical Center's 2023 Accelerator for HealthTech cohort, has raised pre-seed funding. Photo courtesy of TMC

A health tech startup that just collected $1.7 million in pre-seed funding aims to eventually plant its headquarters in Houston.

The startup, Rosarium Health, currently has no headquarters; its 10 employees work remotely from various locations. However, co-founder and CEO Cameron Carter — who lives in the Denver area — says the company is eyeing a future headquarters in Houston.

“We believe Houston is the best city to launch a health care startup, given the Texas Medical Center, diverse talent across health and technology, affordable living, and a city with supportive and progressive communities,” Carter tells InnovationMap. “We feel Houston offers meaningful attributes that can enable a high-growth startup to succeed and for its employees to feel safe.” Continue reading.

Houston-based workforce solutions platform Innovapptive closes series B round

A Houston SaaS company has announced a fresh round of funding. Photo via Innovapptive.com

A Houston software-as-a-service company has closed an undisclosed amount of funding in a series B round.

Innovapptive Inc., which has its global headquarters in Greenway Plaza, has announced it's closed a series B investment round led by Austin-based Vista Equity Partners with support from existing investor Tiger Global Management. The fresh funding will be deployed to "accelerate product innovation and reach new regional markets," according to the company.

“We look forward to this next phase of growth as we continue to define the emerging connected worker software category,” says Sundeep Ravande, founder and CEO of Innovapptive, in the news release. “Vista has significant experience scaling enterprise software businesses and emerging technologies." Continue reading.

Venus Aerospace, a Houston startup with hypersonic engine tech, adds new investor

This Houston company is one step closer to enabling high-speed global travel. Photo courtesy of Venus Aerospace

A Houston-based company that's developing an engine that'll enable one-hour global transportation has announced its latest investor.

Venus Aerospace released the news that Silicon Valley venture capital firm, Airbus Ventures, has joined its team of investors. The supersonic combustion engine technology — more akin to a rocket's engine than an airplane's — is revolutionary because allows for travel at a higher elevation. Jet engines rely on air outside of the aircraft to combust, and rocket engines work with a system that supplies air internally.

“Venus has developed the world’s first liquid-propellant rotating detonation rocket engine (RDRE) with a double-digit percentage increase in efficiency over standard regular engines, making the hypersonic economy possible,” says Sassie Duggleby, CEO and co-founder of Venus, in a news release. “We’re delighted to bring Airbus Ventures into the Venus family and look forward to growing our collaboration as we harness the future of hypersonic flight.” Continue reading.

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Houston essentially matched Austin in venture capital funds received in the third quarter of 2018. Getty Images

Houston neck-and-neck with Austin in third quarter venture capital funding reports

It's on

It was a Texas showdown when it came to venture capital funding between Houston and Austin in the third quarter of 2018. According to Crunchbase data, Houston startups pulled in $138.8 million — 39.2 percent of the state's entire VC funding — while Austin startups reported receiving $150.6 million — 42.6 percent of the funds.

"It's something we've never even come close to before and, all of the sudden, boom, we're right there," Station Houston CEO Gabriella Rowe tells InnovationMap. "I think that's what we are going to continue to see in Houston."

"We're not going to see little wins now. We're going to start seeing big wins."

Before the startup scene can truly celebrate, it's worth noting that the entire state struggled in the third quarter. VCs contributed $353.7 million to Texas startups in 91 known deals, according to the report. That's less than half of what was reported in the second quarter, and, actually, it's less that what Austin alone received in Q2. However, the state is up year-over-year in VC funding by 11 percent, as the state only saw $319.6 million in Q3 of 2017.

Chart courtesy of Crunchbase

Crunchbase reported that the largest four funding rounds in Houston were as follows:

  • OncoResponse (immuno-oncology): $40 million in September
  • ViraCyte (biopharmaceuticals): $30 million in September
  • Enchanted Rock LLC (utilities): $23.6 million in July
  • DNAtriX (cancer treatment): $15.5 million in September
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston ecommerce scale-up company acquires Amazon advertising partner

all aboard

A Houston tech company has tapped an Amazon partner in a strategic acquisition and is bringing the company's full team on board.

Cart.com acquired Ohio-based Amify, a company that provides optimization and advertising solutions. The terms of the deal were not disclosed but Cart.com will on board Amify’s entire employee base, including its founder Ethan McAfee, CEO Chris Mehrabi, and COO Christine McCambridge.

As chief delivery officer, Mehrabi will take the helm of Cart.com’s professional services business and McCambridge will lead Cart.com’s marketplace services team as vice president of marketplace services operations.

“I’m happy to welcome the entire Amify team to Cart.com and have industry veterans Chris Mehrabi and Christine McCambridge join our leadership team,” Cart.com Founder and CEO Omair Tariq says in a news release. “Amify has been widely recognized for their expertise and technology and we’re excited to leverage their experience to help our customers maximize their potential across channels.”

Cart.com's membership will have access to Amify's proprietary technology platform, including advertising, creative content, supply chain strategy, and analytics. The company, which was founded in 2011, currently supports over 50 global brands and manages approximately $1 billion in gross merchandise value. According to LinkedIn, Amify has over 50 employees.

“We could not be more excited to join Cart.com and leverage the company’s resources and scale to deliver value to both our customers and employees,” Mehrabi says. “I’m honored to step into the role of Chief Delivery Officer and contribute to Cart.com’s incredible growth story and innovative reputation.”

Founded in Houston in 2020, Cart.com provides comprehensive physical and digital infrastructure for online merchants. The company raised a $60 million series C and grown its customer base to over 6,000 users. After making several acquisitions, the company also operates 14 fulfillment centers nationwide.

Earlier this year, Tariq sat down with the Houston Innovators Podcast to share a bit about how the company is currently in scale-up mode.

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.